The Status of Humoral Immunity to Parvovirus B19 in Population of Certain Geographical Regions

Cover Page


Cite item

Abstract

Introduction. In a number of countries, including Russia, there is no systematic registration and reporting of parvovirus infection cases; the extent of its spread can be estimated by using humoral immunity rates.

Purpose of the study: Assessment of seroprevalence of parvovirus B19 (B19V) in different age groups of population of Russia, Central Asia, and West Africa.

Materials and methods. A total of 1,732 blood serum samples from residents of St. Petersburg and Nur-Sultan, migrant workers from Uzbekistan and Tajikistan, residents of the Republic of Guinea were studied for IgG antibodies to B19V.

Results. The highest seroprevalence rates were identified in St. Petersburg and Nur-Sultan (62–65%); the lowest rates were registered among migrant workers from Uzbekistan and Tajikistan (47%). The results for the Republic of Guinea showed a B19V seroprevalence rate of 53%. It was found that there is an increasing trend of seropositivity with age; the percentage of seropositive individuals clearly increases in older age groups: up to 55% — among migrant workers from Central Asia and residents of the Republic of Guinea; up to 80–85% — among residents of St. Petersburg and Nur-Sultan.

Discussion. The obtained results confirm the worldwide occurrence of parvovirus infection. People susceptible to infection can cause infection spreading in high-risk groups — among pregnant women, immunodeficient patients, blood product recipients, and cancer patients.

Full Text

Introduction

The medical significance of parvovirus infection (PVI) is attributed to specific features of its patho­gen — human parvovirus B19 (B19V). The virus has a teratogenic effect becoming especially manifest during the second trimester of pregnancy [1-3]. The fetal in­fection results in development of congenital PVI, the most frequent manifestation of which is nonimmune hydrops fetalis [4-7]. B19V is also characterized by a unique tropism for erythroid progenitor cells (pre-erythroblasts) [8]. As a result, Bl9V infection causes disrup­tion of erythropoiesis, which may lead to serious com­plications in patients who are immune compromised or suffer from chronic anemia [9, 10].

Apart from the clinically apparent form of the disease most common among children and known as erythema infectiosum or fifth disease, PVI manifesta­tions are quite diversified. They range from asympto­matic forms (30-50% of all cases) or mild exanthem to arthritis and arthralgia (primarily among adults) as well as severe anemia and development of an aplastic crisis (immunodeficient individuals and patients with hema­tologic disorders) [11-17].

Currently, in a number of countries, including Russia, there is no systematic PVI registration and re­porting; the data on its prevalence are limited, including its prevalence in high-risk groups (pregnant women, blood product recipients) [15, 18-21].

Considering the fact that no PVI preventive me­thods are available and IgG antibodies remain in the blood sera of exposed people for the rest of their life, the extent of PVI spread in a population can be estima­ted by rates of humoral immunity.

The purpose of this study is to assess the deve­lopment of humoral immunity to PVI in different age groups of individuals living in the European part of Russia, countries of Central Asia and West Africa.

Materials and methods

A total of 1,732 blood serum samples from rela­tively healthy adults aged 18-87 were tested for the presence of IgG antibodies to B19V, including 817 serum samples from residents of the Russian Federa­tion (Saint Petersburg), 114 serum samples from mi­grant workers from Central Asia, 480 serum samples from residents of Kazakhstan (Nur-Sultan), 321 se­rum samples from residents of the Republic of Guin­ea (RG). The serum samples were received in 2017­2018 from collections of the virology laboratories of the Saint Petersburg Regional Center for Epidemio­logical Surveillance of Measles and Rubella in the Northwestern Federal District, the Regional Center for Epidemiological Surveillance of Measles in RG. the HIV Etiology and Immunology Laboratory at the Pasteur Research Institute of Epidemiology and Mi­crobiology.

The sera were tested for anti-B19V IgG antibo­dies by using the Anti-Parvovirus B19 ELISA IgG test system (Euroimmun AG, Germany) in accordance with the manufacturer’s protocol.

The data were processed with MS Excel, Prism 5.0 statistical software (GraphPad Software Inc.). The nominal data were described by indicating absolute values and percentages. The nominal data were com­pared by using the Pearson chi-square test to assess the significance of the differences between the actual number of outcomes or qualitative data of the sample falling into each category and the theoretical quanti­ty that could be expected in studied groups if the null hypothesis were true. The chi-square (χ2) value was compared with the critical values for the respective number of degrees of freedom. If the calculated chi- square value was greater than the critical value, it indicated the presence of a statistical relationship be­tween the studied risk factor and the outcome at the respective level of significance.

The Pearson correlation coefficient rxy was used to measure the strength of the relationship between л and y normally distributed variables. The t-test was used to evaluate the statistical significance of the correlative relationship. The values of the rxy correlation coefficient were interpreted in accordance with the Chaddock scale. The probability value of p < 0.05 was used as the threshold for significant differences.

Results

The status of humoral immunity to parvovirus B19 among relatively healthy residents of Saint Petersburg (Russia)

Blood serum samples of relatively healthy resi­dents of Saint Petersburg (n = 317) were collected from individuals aged 18-87 (the mean age was 42.3 ± 12.09 years; the median age was 39 years). The total per­centage of males was 32.8%, while females account­ed for 67.2%. The serum samples were divided into 4 age groups. Anti-B19V IgG antibodies were found in 62.1 ± 2.7% (197 of 317) samples and in each of the four groups (Table 1).

 

Table 1. Identification of anti-B19V IgG antibodies in the blood serum of relatively healthy residents of Saint Petersburg (n = 317) in different age groups

Age, years

The number of examined sera

Of these, IgG+ to B19V

abs.

%, М ± m

18-201

18

6

33,3 ± 11,1

21–302

68

40

58,8 ± 5,9

18-30

86

46

53,5 ± 5,3

31-403

78

40

51,3 ± 5,6

≥414

153

111

72,5 ± 3,6

Total

317

197

62,1 ± 2,7

Note. Significance of differences: p1-4 < 0.001.

 

The smallest proportion of seropositive indivi­duals was identified in the 18-20 year-old group where it was 33.3 ± 11.1%. The proportion of positive anti- B19V IgG samples increases with age. The total pro­portion of positive samples among 18-30 year-old in­dividuals was 53.5 ± 5.3%, while the largest proportion of positive findings (72.5 ± 3.6%) was identified in the age group of 41 years and older. The identified differ­ences are statistically significant (df = 3; χ2 = 17.623; p < 0.001).

The gender analysis did not reveal any substan­tial differences between seropositive males and fe­males: 66.5 and 62.0% respectively (df = 3; χ2 = 2.399; p = 0.494). The proportion of seropositive females was slightly higher in the age groups of 18-20 years and 41 years and older; seropositive males were more fre­quently found in the age range of 21-40 years.

Thus, among the relatively healthy residents of Saint Petersburg, around 62% were identified as B19V-seropositive and their proportion tends to in­crease in older age groups, without demonstrating any significant gender-based differences.

A totally different pattern of building herd immu­nity against B19V was observed in the organized group made up staff and cadets (having special living accom­modations) of a military college in Saint Petersburg. 500 blood serum samples from individuals aged 18-60 (the mean age was 25.2 years; median age was 21 years) were tested. Most of the examined were males (91.6%). In the organized group, the B19V seroprevalence was much higher (p = 0.005) than its average rate observed among city residents, and amounted to 85.8 ± 1.56% (Table 2). The distinctive feature of the above popula­tion is a large number (190 of 223) of B19V-seroposi- tive individuals among the cadets of 18-20 years: Their proportion was 85.2 ± 2.38%. The high level of humoral immunity remained in all examined age groups, without any statistically significant changes.

 

Table 2. Identification of anti-B19V IgG antibodies in blood samples of healthy individuals from an organized team (n = 500) in different age groups

Age, years

The number of examined sera

Of these, IgG+ to B19V

abs.

%, М ± m

18-20

223

190

85,2 ± 2,3

21-30

173

145

83,8 ± 2,8

31-40

64

60

93,8 ± 3,0

>41

40

34

85,0 ± 5,6

Total

500

426

85,8 ± 1,5

The proportion of IgG-positive samples was higher among males (86.7 ± 1.59%) than among fe­males (69.0 ± 7.13%), though the low number of the females examined in this population (42 females of 500 individuals) provides no conclusion that the identified gender differences can be deemed significant.

Thus, in the environment characterized by long­term close contact (living in barracks) the herd immu­nity against B19V was actively developing among the individuals of the first age group (18-20 years), which presumably can be explained by undetected circulation of the virus in this population.

The status of humoral immunity to parvovirus B19 among migrant workers from countries of Central Asia

Lately the spread of bacterial and viral infections has demonstrated an increasing trend due to active mi­gration processes. A large number of migrant workers come annually to Russia from countries of Central Asia. Generally, there is no information about circulation of pathogens of infectious diseases, including PVI, in this group.

Below are the results obtained by the study of hu­moral immunity to B19V among Central Asian migrant workers staying in Saint Petersburg on a work visa. The proportion of IgG-positive individuals should be estimated to identify the significance of this population in PVI prevalence among migrant workers and among permanent residents of Saint Petersburg.

To identify IgG antibodies to B19V, a total of 114 blood serum samples were studied. The samples were collected from migrant workers from Uzbekistan and Tajikistan (104 males and 10 females) aged 18-56 years (the mean age was 33.4 years; the median age was 33.5 years) and divided into three age groups (Table 3). Altogether, the quantity and proportion of IgG-positive samples amounted to 54 of 114 (47.4 ± 4.6%). Anti- B19V IgG antibodies were found in each age group.

 

Table 3. Identification of anti-B19V IgG antibodies in blood samples of labor migrants from Central Asia (n = 114) in different age groups

Age, years 

The number of examined sera

Of these, IgG+ to B19V  

abs.

%, М ± m

18–30

50

19

38,0 ± 6,8

31–40

33

18

54,5 ± 8,6

≥41

31

17

54,8 ± 8,9

Total

114

54

47,4 ± 4,6

On the whole, IgG-positive serum samples col­lected from 18-30 year-old individuals accounted for 38.0 ± 6.8% of the samples. In individuals older than 31 years, the proportion of samples containing IgG an­tibodies to B19V increased on average to 54.6% and stayed at this level.

The proportion of seropositive migrant workers aged 30 years and younger was slightly lower than the proportion of seropositive residents of Saint Petersburg in the same age group: 38.0 and 53.5% respectively (the differences are not statistically significant). Significant (p = 0.05) differences are found in the group of individuals aged 41 years and older: 54% seropositive individuals among the migrant workers and 72.5% se­ropositive individuals among permanent residents of Saint Petersburg.

The proportion of seropositive males and females was comparable: 48.1 ± 7.1% against 40.0 ± 7.1% re­spectively. However, females accounted for less than 10% of the examined in this group, thus giving no proof of significance of the obtained results.

The examined blood samples were collected from migrant workers who came to Saint Petersburg from Central Asian low-density areas. This fact may ex­plain the lower number of B19V-seropositive individ­uals among residents of Uzbekistan and Tajikistan as compared to residents of Saint Petersburg. On the other hand, there can also be a correlation between the B19V herd immunity rate and the ethnic affiliation of the ex­amined individuals.

To prove this assumption regarding IgG antibo­dies to B19V, we examined blood samples from resi­dents of another country of the Eurasian continent — Kazakhstan.

The status of humoral immunity to B19V among relatively healthy residents of Nur-Sultan (Republic of Kazakhstan)

The comparative study was performed by using samples collected from individuals living in Nur-Sultan, the capital of Kazakhstan. The city is comparable with Saint Petersburg by density of population, the num­ber of educational (secondary and higher) institutions, manufacturing companies, military schools, etc. The city is characterized by active internal and external mi­gration supported by well-developed rail and air traffic.

A total of 480 blood serum samples were studied. The samples were collected from relatively healthy Nur-Sultan residents aged 18-59 years (the mean age was 30.5 ± 9.8 years; the median age was 28 years). The males and females accounted for 73.7% and 26.3%, re­spectively. Anti-B19V IgG antibodies were found in 65.2 ± 2.2% of the samples. The serum samples were divided into 5 age groups; IgG-positive samples were found in each of them. The analysis of the data from Table 4 revealed a growth trend for the proportion of seropositive samples in older age groups (r = 0.225; p = 0.000001). The lowest proportion of seropositive serum samples accounting for 48.6 ± 5.8% was iden­tified among individuals aged 18-20 years. In the age groups of 21-30 and 31-40 years, the proportion of seropositive individuals increased to 62.0 ± 3.3 and 69.9 ± 4.3% respectively. In the group of individuals aged 41 years and older, the proportion of those who were IgG positive to B19V reached 80.5 ± 4.2%. The found differences are statistically significant (df = 3; χ2 = 19.696; p < 0.001). The proportion of males with IgG antibodies to B19V was higher than the proportion of seropositive females: 69.5 ± 2.9% and 53.2 ± 6.1% respectively (df = 1; χ2 = 10.368; p = 0.002).

 

Table 4. Identification of anti-B19V IgG antibodies in the blood serum of relatively healthy residents of Nur-Sultan (n = 480) in different age groups

Age, years 

The number of examined sera

Of these IgG+ to B19V 

abs.

%, М ± m 

18-201

72

35

48,6 ± 5,8

21-302

208

129

62,0 ± 3,3

18-30

280

164

58,6 ± 2,9

31-403

113

79

69,9 ± 4,3

≥41 4

87

70

80,5 ± 4,2

Total

480

313

65,2 ± 2,2

Note. Significance of differences: p1-4 < 0.001.

The greatest differences were observed in the group of young people aged 18-20 years; the propor­tion of seropositive males was 2.7 times as high as the proportion of females protected against infection: 67.5 ± 2.9 and 25.0 ± 5.2% respectively. The differenc­es are statistically significant (p = 0.0004). In the age group of 21-30 years, the differences tend to decrease: 65.1 ± 3.4% of seropositive males and 47.2 ± 6.1% of seropositive females; in the group of individuals aged 31 years and older, the proportions of seropositive males and females become equal.

The status of humoral immunity to B19V among relatively healthy residents of RG

The obtained results helped identify special char­acteristics of building herd immunity against B19V in Eurasian countries interconnected through close com­munication, migration flows, trade, cultural and inter­personal contacts. The African continent geographically remote from Eurasian countries has its own economic, social, and ethnic distinctive features. The herd immu­nity against B19V and its development were assessed through examination of blood samples collected from RG residents living in Conakry and Kindia, the Mamou, Labe, Nzerekore, Kankan, Faranah, and Boke regions.

A total of 321 blood serum samples from males and females aged 18-83 years (the mean age was 35.6 years; the median age was 32 years) were exam­ined and divided into 4 age groups. When divided by gender, the number of samples was almost the same. The males accounted for 50.1%, while the females ac­counted for 49.9% of the samples.

Anti-B19V IgG antibodies were found in each age group. On the whole, the proportion of IgG-positive samples was 53.9 ± 2.78% (173 of 321). The results are shown in Table 5.

 

Table 5. Identification of anti-B19V IgG antibody in blood samples of healthy residents of the Republic of Guinea (n = 321) in different age groups

Age, years 

The number of examined sera

Of these IgG+ to B19V 

abs.

%, М ± m 

18-20

18

8

44,4 ± 11,7

21-30

78

42

53,8 ± 5,6

18-30

96

50

52,1 ± 5,1

31-40

88

47

53,4 ± 5,3

≥41

137

76

55,5 ± 4,2

Total

321

173

53,9 ± 2,7

The lowest proportion of seropositive samples was registered in the group of 18-20 years (44.4 ± 11.7%). In the age group of 21-30 years, the proportion of se­ropositive samples increased to 53.8 ± 5.6%. In total, the proportion of seropositive individuals aged 18 to 30 years was 52.1 ± 5.1% and showed no considerable changes in the older age groups.

Generally, the proportions of seropositive males and females did not demonstrate any substantial differ­ences: 57.4 and 47.9% respectively. However, the age groups of 18-20 and 31-40 years demonstrate a signifi­cantly larger number of seropositive males as compared to the females protected from infection: 57.1% against 36.4% and 59.4% against 31.6%, respectively. In the groups of 21-30 years as well as those of 41 years and older, the proportions of seropositive males and females did not show any substantial differences, staying at the level of 51.2-57.1%.

Thus, IgG antibodies to B19V were found nearly in fifty percent of the samples from the first age group (18-20 years). Comparable data were also obtained for individuals of this age group in other regions (Russia, Kazakhstan).

Discussion

With no virus-specific preventive measures, there is clear evidence of continuous B19V circulation in differ­ent regions of the world [22]. In this study, IgG antibo­dies to B19V were found in all age groups of relatively healthy residents of Russia, Central Asia (Eurasia) and RG (West Africa). The study also revealed that B19V seroprevalence rates tend to increase among individuals of older ages in all studied groups, thus supporting the data obtained by other authors [12, 17, 18]. At the same time, the study also revealed differences in development of herd immunity among residents of different countries.

The highest rates of seroprevalence were iden­tified in Saint Petersburg and Nur-Sultan; the lowest rates were found among migrant workers from sparse­ly populated regions of Uzbekistan and Tajikistan. The B19V seroprevalence rate fell in between the estimated rates for blood samples collected both from residents of the capital (Conakry) and from residents of sparsely populated regions of RG.

Large metropolitan cities (Saint Petersburg and Nur-Sultan) characterized by high density of popula­tion, pronounced migration processes, high percentage of organized children attending preschool and school, a large number of students of secondary and higher schools (including military schools), where nonresident students live in dormitories and barracks, produce con­ditions favorable for active circulation of B19V.

Indeed, the development pattern for Nur-Sultan residents’ herd immunity against B19V correlates to the data obtained from testing blood serum samples of relatively healthy residents of Saint Petersburg. The ag­gregate portions of seropositive individuals aged 18-30 years were 58.6 ± 2.9 and 53.5 ± 5.3% respectively, exceeding the proportion identified when testing blood serum samples from migrant workers from Uzbekistan and Tajikistan — 38.0 ± 6.8%. The proportions of sero­positive individuals older than 41 years are also compa­rable: 72.5 ± 3.6% in Saint Petersburg and 80.5 ± 4.2% in Nur-Sultan.

The fact that long-term close contacts contribute to the spread of infection is supported by high rates of seroprevalence among cadets of the military college in Saint Petersburg, where the actively developing herd immunity against B19V (85.2% seropositive) was reg­istered among 18-20 year-old individuals and substan­tially exceeded the seroprevalence rates observed in the similar age group of relatively healthy residents of Saint Petersburg (33.3%).

The examined Central Asian migrant workers came from areas characterized by low density of pop­ulation, poorly pronounced internal migration, a small number of secondary specialized colleges and higher schools. These features may explain the considerably lower numbers of B19V seropositive individuals among residents of Uzbekistan and Tajikistan as compared to residents of Saint Petersburg. Migrant workers having low herd immunity are undoubtedly a target of B19V infection. The overcrowded accommodation typical of their staying in Saint Petersburg can contribute to ac­tive spread of infection, which can involve susceptible permanent residents of the city, including blood donors, pregnant women, individuals with primary and second­ary immunodeficiencies, patients suffering from ane­mia, blood product and bone marrow recipients, cancer patients.

The presence of gender-based differences in de­velopment of herd immunity against B19V is most likely connected with social factors and was observed during examination of blood serum samples from re­sidents of Kazakhstan and RG. In Nur-Sultan, humor­al immunity to B19V developed more actively among males aged 18-20 years. These results may evidence a more active circulation of the virus among young males of Nur-Sultan.

The examined residents of RG also demonstra­ted almost a two-fold increase in the number of B19V seropositive young males as compared to seropositive females of the similar age groups, which is comparable with the gender differences identified among residents of Nur-Sultan. The prevalence of seropositive females was observed in older age groups of RG residents, which may be explained by closer contacts between women and children in families.

In the meantime, in each examined group of resi­dents from different geographical regions there were al­so identified seronegative individuals, thus suggesting that individuals from high-risk groups can be involved in an infectious process. Previously it was shown that around 50% of the examined pregnant women living in Saint Petersburg were susceptible to B19V infection [23]. It is found that parvovirus B19 infection of pa­tients suffering from chronic anemia as well as cancer patients can aggravate the course and the prognosis of the primary disease [24, 25].

The obtained results confirm the significance of PVI not only for children and teenagers, but also for adults. The continuous identification of PVI cases in different age groups of individuals living in the North­western Federal District is supported by the previously performed studies [26]. The seroprevalence of B19V was assessed by a number of foreign authors studying blood donors from South Africa, Iran, China, Brazil [27-30]. B19V-seropositive individuals were identified in each of the performed studies, thus supporting the fact of wide spread of PVI. Their proportion in the tar­get group ranged from 27.6% (Iran) to 62.2% (RSA), on the whole, correlating to our data and evidencing the existence of factors affecting development of herd immunity against B19V.

Conclusion

The obtained results confirm the PVI prevalence in different geographical regions. Herd immunity de­velops most actively in long-term close contact envi­ronments.

At the same time, the study revealed seronegative individuals in all the groups. The presence of individ­uals susceptible to infection can lead to spread of in­fection in high-risk groups — among pregnant women, individuals with primary and secondary immunodefi­ciencies, patients suffering from anemia, blood product and bone marrow recipients, cancer patients.

×

About the authors

Irina N. Lavrentieva

St. Petersburg Pasteur Institute

Author for correspondence.
Email: pasteur.lawr@mail.ru
ORCID iD: 0000-0002-2188-6547
D. Sci. (Med.), Chief, Laboratory of experimental virology Россия

Irina V. Khamitova

St. Petersburg Pasteur Institute

Email: div-o@mail.ru
ORCID iD: 0000-0003-1966-7860
Chief, Central clinic diagnostic laboratory Россия

Jacob Camara

Gamal Abdel Nasser University

Email: jacob2240@gmail.com
ORCID iD: 0000-0003-4837-0206
researcher, laboratory of hemorrhagic fevers Гвинея

Anastasia Yu. Antipova

St. Petersburg Pasteur Institute

Email: anti130403@mail.ru
ORCID iD: 0000-0002-7763-535X
PhD (Biol.), researcher, Laboratory of experimental virology Россия

Maina A. Bichurina

St. Petersburg Pasteur Institute

Email: fake@neicon.ru
ORCID iD: 0000-0001-5184-0315
D. Sci. (Med.), Chief, Virology laboratory, Center for the elimination of measles and rubella Россия

Faly N. Magassouba

Gamal Abdel Nasser University

Email: cmagassouba01@gmail.com
ORCID iD: 0000-0002-3760-6642
PhD, Chief, Laboratory of hemorrhagic fevers Гвинея

Oleg N. Nikishov

S.M. Kirov Military Medical Academy

Email: nikishov.oleg2015@yandex.ru
ORCID iD: 0000-0002-3677-1734
PhD (Med.), lecturer of the Department of general and military epidemiology Россия

Alexander A. Kuzin

S.M. Kirov Military Medical Academy

Email: paster-spb@mail.ru
ORCID iD: 0000-0001-9154-7017
D. Sci. (Med.), Assoc. Prof., Department of general and military epidemiology Россия

Alexander V. Semenov

St. Petersburg Pasteur Institute;
North-Western State Medical University named after I.I. Mechnikov

Email: alexvsemenov@yahoo.com
ORCID iD: 0000-0003-3223-8219
D. Sci. (Biol.), Chief, Laboratory of HIV immunology and virology, Vice-director Россия

References

  1. Levy R., Weissman A., Blomberg G., Hagay Z.J. Infection by parvovirus B19 during pregnancy: a review. Obstet. Gynecol. Surv. 1997; 52(4):254-9. DOI: http://doi.org/10.1097/00006254-199704000-00023
  2. Васильев В.В., Мурина Е.А., Сидоренко С.В., Мукомолова А.Л., Куюмчъян С.Х., Воронина О.Л. и др. Парвовирусная (В19V) инфекция у беременных и детей раннего возраста. Журнал инфектологии. 2011; 3(4): 26-33. DOI: http://doi.org/10.22625/2072-6732-2011-3-4-26-33
  3. Puccetti C., Contoli M., Bonvicini F., Cervi F., Simonazzi G., Gallinella G., et al. Parvovirus B19 in pregnancy: possible consequences of vertical transmission. Prenatal Diagnosis. 2012; 32(9): 897-902. DOI: http://doi.org/10.1002/pd.3930
  4. Курцер М.А., Гнетецкая В.А., Мальмберг О.Л., Белковская М.Э., Лукаш Е.Н., Шипулин Г.А. и др. Неиммунная водянка плода: диагностика и тактика. Акушерство и гинекология. 2009; (2): 37-40.
  5. Лушнова И.В. Парвовирусная В19 инфекция. Педиатр. 2010; 1(2): 115-8.
  6. Макаров О.В., Алешкин В.А., Савченко Т.Н., ред. Инфекции в акушерстве и гинекологии. М.: МЕДпресс-информ; 2007.
  7. Lassen J., Jensen A.K., Bager P., Pedersen C.B., Panum I., Nørgaard-Pedersen B., et al. Parvovirus B19 infection in the first trimester of pregnancy and risk of fetal loss: a population-based case-control study. Am. J. Epidemiol. 2012; 176(9): 803-7. DOI: http://doi.org/10.1093/aje/kws177
  8. Wong S., Zhi N., Filippone C., Keyvanfar K., Kajigaya S., Brown K.E., et al. Ex Vivo-generated CD36+ erythroid progenitors are highly permissive to Human Parvovirus B19 replication. J. Virol. 2008; 82(5): 2470-6. DOI: http://doi.org/10.1128/ JVI.02247-07
  9. Munakata Y., Saito-Ito T., Kumura-Ishii K., Huang J., Kodera T., Ishii T., et al. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood. 2005; 106(10): 3449- 56. DOI: http://doi.org/10.1182/blood-2005-02-0536
  10. Bua G., Manaresi E., Bonvicini F., Gallinella G. Parvovirus B19 replication and expression in differentiating erythroid progenitor cells. PLoS One. 2016; 11(2): e0148547. DOI: http://doi.org/10.1371/journal.pone.0148547
  11. Lefrère J.J., Servant-Delmas A., Candotti D., Mariotti M., Thomas I., Brossard Y., et al. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood. 2005; 106(8): 2890-5. DOI: http://doi.org/10.1182/blood-2005-03-1053
  12. Никишов О.Н., Кузин А.А., Антипова А.Ю., Лаврентьева И.Н. Клинико-эпидемиологические особенности и профилактика парвовирусной инфекции. Военно-медицинский журнал. 2016; 337(8): 45-50.
  13. Win N., Lee E., Needs M., Homeida S., Stasi R. Profound sustained reticulocytopenia and anaemia in an adult patient with sickle cell disease. Transfus. Med. 2014; 24(6): 418-20. DOI: http://doi.org/10.1111/tme.12168
  14. Чернова Т.М., Дубко М.Ф. Парвовирус B19 как причина кардита в сочетании с миозитом. Медицинский совет. 2018; (2): 190-3. DOI: http://doi.org/10.21518/2079-701X-2018-2-190-193
  15. Элижбаева М.А., Февралева И.С., Глинщикова О.А., Сильвейстрова О.Ю., Шипулина О.Ю., Домонова Э.А. и др. Выявление парвовируса В19 в крови российских доноров. Гематология и трансфузиология. 2011; 56(2): 10-3.
  16. Riipinen A., Väisänen E., Nuutila M., Sallmen M., Karikoski R., Lindbohm M.L., et al. Parvovirus B19 infection in fetal deaths. Clin. Infect. Dis. 2008; 47(12): 1519-25. DOI: http://doi.org/10.1086/593190
  17. Kelly H.A., Siebert D., Hammond R., Leydon J., Kiely P., Maskill W. The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiol. Infect. 2000; 124(3): 449-57. DOI: http://doi.org/10.1017/s0950268899003817
  18. Mossong J., Hens N., Friederichs V., Davidkin I., Broman M., Litwinska B., et al. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection, and maternal risk of infection. Epidemiol. Infect. 2008; 136(8): 1059-68. DOI: http://doi.org/10.1017/S0950268807009661
  19. Elnifro E., Nisha A.K., Almabsoot M., Daeki A., Mujber N., Muscat J. Seroprevalence of parvovirus B19 among pregnant women in Tripoli, Libya. J. Infect. Dev. Ctries. 2009; 3(3): 218-20. DOI: http://doi.org/10.3855/jidc.38
  20. Pedranti M.S., Barbero P., Wolff C., Ghietto L.M., Zapata M., Adamo M.P. Infection and immunity for human parvovirus B19 in patients with febrile exanthema. Epidemiol. Infect. 2012; 140(3): 454-61. DOI: http://doi.org/10.1017/S0950268811000823
  21. Nicolay N., Cotter S. Clinical and epidemiological aspects of parvovirus B19 infections in Ireland, January 1996 – June 2008. Eurosurveill. 2009; 14(25): 19249.
  22. Лаврентьева И.Н., Антипова А.Ю. Парвовирус B19 человека: характеристика возбудителя, распространение и диагностика обусловленной им инфекции. Инфекция и иммунитет. 2013; 3(4): 311-22.
  23. Антипова А.Ю., Лаврентьева И.Н., Бичурина М.А., Лялина Л.В., Кутуева Ф.Р. Распространение парвовирусной инфекции в Северо-Западном федеральном округе России. Журнал инфектологии. 2011; 3(4): 44-8.
  24. Khamitova I.V., Lavrentyeva I.N., Averyanova M.Yu., Chukhlovin A.B., Zubarovskaya L.S., Afanasyev B.V. Parvovirus B19 incidence, specific antibody response, and delayed hematopoietic recovery after allogeneic hematopoietic stem cell transplantation. Cell. Ther. Transplant. 2018; 7(1): 36-43. DOI: http://doi.org/10.18620/ctt-1866-8836-2018-7-1-36-43
  25. Лаврентьева И.Н., Хамитова И.В., Слита А.В., Левковский А.Е., Диало А.А., Диало А.К. и др. Влияние коинфицирования B19V и Plasmodium Falciparum на течение и прогноз малярии. Инфекция и иммунитет. 2018; 8(3): 383-7. DOI: http://doi.org/10.15789/2220-7619-2018-3-383-387
  26. Лаврентьева И.Н., Антипова А.Ю., Бичурина М.А., Хамитова И.В., Никишов О.Н., Кузин А.А. Маркеры парвовирусной инфекции у лиц с экзантемными заболеваниями и в группах риска. Журнал инфектологии. 2019; 11(3): 110-7.
  27. Francois K.L., Parboosing R., Moodley P. Parvovirus B19 in South African blood donors. J. Med. Virol. 2019; 91(7): 1217‐23. DOI: http://doi.org/10.1002/jmv.25450
  28. Zadsar M., Aghakhani A., Banifazl M., Kazemimanesh M., Tabatabaei Yazdi S.M., Mamishi S., et al. Seroprevalence, molecular epidemiology and quantitation of parvovirus B19 DNA levels in Iranian blood donors. J. Med. Virol. 2018; 90(8): 1318-22. DOI: http://doi.org/10.1002/jmv.25195
  29. Li X., Lin Z., Liu J., Tang Y., Yuan X., Li N., et al. Overall prevalence of human parvovirus B19 among blood donors in mainland China: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2020; 99(17): e19832. DOI: http://doi.org/10.1097/MD.0000000000019832
  30. Slavov S.N., Rodrigues E.S., Sauvage V., Caro V., Diefenbach C.F., Zimmermann A.M., et al. Parvovirus B19 seroprevalence, viral load, and genotype characterization in volunteer blood donors from southern Brazil. J. Med. Virol. 2019; 91(7): 1224‐31. DOI: http://doi.org/10.1002/jmv.25453

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Lavrentieva I.N., Khamitova I.V., Camara J., Antipova A.Y., Bichurina M.A., Magassouba F.N., Nikishov O.N., Kuzin A.A., Semenov A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies